CD19
背景(考古学)
CD8型
免疫学
细胞毒性T细胞
生物
T细胞
白血病
B细胞
基因签名
嵌合抗原受体
抗原
医学
免疫系统
基因
遗传学
基因表达
抗体
体外
古生物学
作者
Nathaniel D. Anderson,Jack Birch,Théo Accogli,Ignacio Criado,Eleonora Khabirova,Conor Parks,Yvette Wood,Matthew D. Young,Tarryn Porter,Rachael T. Richardson,Sarah J. Albon,Bilyana Popova,Andre Lopes,Robert Wynn,Rachael Hough,Satyen H. Gohil,Martin Pulé,Persis Amrolia,Sam Behjati,Sara Ghorashian
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2023-07-01
卷期号:29 (7): 1700-1709
被引量:73
标识
DOI:10.1038/s41591-023-02415-3
摘要
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. We show that long-lived CAR-T cells developed a CD4/CD8 double-negative phenotype with an exhausted-like memory state and distinct transcriptional signature. This persistence signature was dominant among circulating CAR-T cells in all children with a long-lived treatment response for which sequencing data were sufficient (4/4, 100%). The signature was also present across T cell subsets and clonotypes, indicating that persisting CAR-T cells converge transcriptionally. This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. Examination of single T cell transcriptomes from a wide range of healthy and diseased tissues across children and adults indicated that the persistence signature may be specific to long-lived CAR-T cells. These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists.
科研通智能强力驱动
Strongly Powered by AbleSci AI